Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells. 2015

Yusuke S Hori, and Ryusuke Hosoda, and Yukinori Akiyama, and Rio Sebori, and Masahiro Wanibuchi, and Takeshi Mikami, and Toshiya Sugino, and Kengo Suzuki, and Mitsuhisa Maruyama, and Miki Tsukamoto, and Nobuhiro Mikuni, and Yoshiyuki Horio, and Atsushi Kuno
Department of Pharmacology, Sapporo Medical University School of Medicine, South-1, West-17, Chuo-ku, Sapporo, 060-8556, Japan.

Mitochondrial autophagy eliminates damaged mitochondria and decreases reactive oxygen species (ROS). The autophagy inhibitor chloroquine (CQ) potentiates temozolomide (TMZ) cytotoxicity in glioma cells, but it is not known whether CQ does this by inhibiting mitochondrial autophagy. The effects of CQ and TMZ on MitoSOX Red fluorescence, a mitochondrial ROS indicator, and cell death were examined in rat C6 glioma cells. Mitochondrial autophagy was monitored by the colocalization of MitoTracker Red fluorescence and EGFP-LC3 dots. Mitochondrial content was measured by MitoTracker Green fluorescence and immunoblotting for a mitochondrial protein. Finally, CQ's effects on tumor cells derived from a glioblastoma patient and human U87-MG glioblastoma cells were assessed. TMZ (100-1,000 μM) alone did not affect mitochondrial ROS or cell death in C6 cells, but when administered with CQ (10 μM), it increased mitochondrial ROS and cell death. Antioxidants significantly suppressed the CQ-augmented cell death in TMZ-treated cells, indicating that mitochondrial ROS were involved in this cell death. TMZ treatment reduced MitoTracker Green fluorescence and mitochondrial protein levels, and these effects were inhibited by CQ. TMZ also increased the colocalization of EGFP-LC3 dots with mitochondria, and CQ enhanced this effect. CQ potentiated TMZ-induced cytotoxicity in patient-derived glioblastoma cells as well as human U87-MG glioblastoma cells. These results suggest that CQ increases cellular ROS and augments TMZ cytotoxicity in glioma cells by inhibiting mitochondrial autophagy.

UI MeSH Term Description Entries
D008928 Mitochondria Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Each mitochondrion is surrounded by a double limiting membrane. The inner membrane is highly invaginated, and its projections are called cristae. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP. They contain distinctive RIBOSOMES, transfer RNAs (RNA, TRANSFER); AMINO ACYL T RNA SYNTHETASES; and elongation and termination factors. Mitochondria depend upon genes within the nucleus of the cells in which they reside for many essential messenger RNAs (RNA, MESSENGER). Mitochondria are believed to have arisen from aerobic bacteria that established a symbiotic relationship with primitive protoeukaryotes. (King & Stansfield, A Dictionary of Genetics, 4th ed) Mitochondrial Contraction,Mitochondrion,Contraction, Mitochondrial,Contractions, Mitochondrial,Mitochondrial Contractions
D002738 Chloroquine The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. Aralen,Arechine,Arequin,Chingamin,Chlorochin,Chloroquine Sulfate,Chloroquine Sulphate,Khingamin,Nivaquine,Sulfate, Chloroquine,Sulphate, Chloroquine
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077204 Temozolomide A dacarbazine derivative that is used as an alkylating antineoplastic agent for the treatment of MALIGNANT GLIOMA and MALIGNANT MELANOMA. 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one,CCRG 81045,CCRG-81045,M&B 39831,M&B-39831,Methazolastone,NSC 362856,NSC-362856,TMZ-Bioshuttle,TMZA-HE,Temodal,Temodar,Temozolomide Hexyl Ester,CCRG81045,M&B39831,NSC362856,TMZ Bioshuttle
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial
D001343 Autophagy The segregation and degradation of various cytoplasmic constituents via engulfment by MULTIVESICULAR BODIES; VACUOLES; or AUTOPHAGOSOMES and their digestion by LYSOSOMES. It plays an important role in BIOLOGICAL METAMORPHOSIS and in the removal of bone by OSTEOCLASTS. Defective autophagy is associated with various diseases, including NEURODEGENERATIVE DISEASES and cancer. Autophagocytosis,ER-Phagy,Lipophagy,Nucleophagy,Reticulophagy,Ribophagy,Autophagy, Cellular,Cellular Autophagy,ER Phagy

Related Publications

Yusuke S Hori, and Ryusuke Hosoda, and Yukinori Akiyama, and Rio Sebori, and Masahiro Wanibuchi, and Takeshi Mikami, and Toshiya Sugino, and Kengo Suzuki, and Mitsuhisa Maruyama, and Miki Tsukamoto, and Nobuhiro Mikuni, and Yoshiyuki Horio, and Atsushi Kuno
September 2016, BMC neurology,
Yusuke S Hori, and Ryusuke Hosoda, and Yukinori Akiyama, and Rio Sebori, and Masahiro Wanibuchi, and Takeshi Mikami, and Toshiya Sugino, and Kengo Suzuki, and Mitsuhisa Maruyama, and Miki Tsukamoto, and Nobuhiro Mikuni, and Yoshiyuki Horio, and Atsushi Kuno
January 2022, Computational intelligence and neuroscience,
Yusuke S Hori, and Ryusuke Hosoda, and Yukinori Akiyama, and Rio Sebori, and Masahiro Wanibuchi, and Takeshi Mikami, and Toshiya Sugino, and Kengo Suzuki, and Mitsuhisa Maruyama, and Miki Tsukamoto, and Nobuhiro Mikuni, and Yoshiyuki Horio, and Atsushi Kuno
December 2014, Neurosurgical focus,
Yusuke S Hori, and Ryusuke Hosoda, and Yukinori Akiyama, and Rio Sebori, and Masahiro Wanibuchi, and Takeshi Mikami, and Toshiya Sugino, and Kengo Suzuki, and Mitsuhisa Maruyama, and Miki Tsukamoto, and Nobuhiro Mikuni, and Yoshiyuki Horio, and Atsushi Kuno
April 2004, Cell death and differentiation,
Yusuke S Hori, and Ryusuke Hosoda, and Yukinori Akiyama, and Rio Sebori, and Masahiro Wanibuchi, and Takeshi Mikami, and Toshiya Sugino, and Kengo Suzuki, and Mitsuhisa Maruyama, and Miki Tsukamoto, and Nobuhiro Mikuni, and Yoshiyuki Horio, and Atsushi Kuno
October 2011, Chinese journal of cancer,
Yusuke S Hori, and Ryusuke Hosoda, and Yukinori Akiyama, and Rio Sebori, and Masahiro Wanibuchi, and Takeshi Mikami, and Toshiya Sugino, and Kengo Suzuki, and Mitsuhisa Maruyama, and Miki Tsukamoto, and Nobuhiro Mikuni, and Yoshiyuki Horio, and Atsushi Kuno
February 2021, Aging,
Yusuke S Hori, and Ryusuke Hosoda, and Yukinori Akiyama, and Rio Sebori, and Masahiro Wanibuchi, and Takeshi Mikami, and Toshiya Sugino, and Kengo Suzuki, and Mitsuhisa Maruyama, and Miki Tsukamoto, and Nobuhiro Mikuni, and Yoshiyuki Horio, and Atsushi Kuno
November 2016, Cancer investigation,
Yusuke S Hori, and Ryusuke Hosoda, and Yukinori Akiyama, and Rio Sebori, and Masahiro Wanibuchi, and Takeshi Mikami, and Toshiya Sugino, and Kengo Suzuki, and Mitsuhisa Maruyama, and Miki Tsukamoto, and Nobuhiro Mikuni, and Yoshiyuki Horio, and Atsushi Kuno
June 2019, European journal of pharmacology,
Yusuke S Hori, and Ryusuke Hosoda, and Yukinori Akiyama, and Rio Sebori, and Masahiro Wanibuchi, and Takeshi Mikami, and Toshiya Sugino, and Kengo Suzuki, and Mitsuhisa Maruyama, and Miki Tsukamoto, and Nobuhiro Mikuni, and Yoshiyuki Horio, and Atsushi Kuno
July 2015, Oncology letters,
Yusuke S Hori, and Ryusuke Hosoda, and Yukinori Akiyama, and Rio Sebori, and Masahiro Wanibuchi, and Takeshi Mikami, and Toshiya Sugino, and Kengo Suzuki, and Mitsuhisa Maruyama, and Miki Tsukamoto, and Nobuhiro Mikuni, and Yoshiyuki Horio, and Atsushi Kuno
January 2019, Journal of neuro-oncology,
Copied contents to your clipboard!